Search Results

You are looking at 1 - 10 of 18 items for :

  • "tocilizumab" x
Clear All
Orvosi Hetilap
Authors: Botond Lakatos, László Gopcsa, Enikő Gondos, Alexandra Riczu, Zsuzsa Várnai, Éva Nagy, Eszter Molnár, Gabriella Bekő, Ilona Bobek, Péter Reményi, János Szlávik, János Sinkó and István Vályi-Nagy

] 5 Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J

Open access

–1048. 39 Lurati, A., Bertani, L., Re, K. A., et al.: Successful treatment of a patient with giant cell vasculitis (Horton arteritis) with tocilizumab a humanized anti-interleukin-6 receptor

Restricted access

60 2272 2283 Emery, P., Keystone, E., Tony, H. P. és mtsai: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in

Restricted access
Orvosi Hetilap
Authors: Ilona Bobek, László Gopcsa, Marienn Réti, Gabriella Bekő, Lilla Hancz, Botond Lakatos, Eszter Molnár, Sándor Nagy, Péter Reményi, Gabriella Sebestyén, János Sinkó, János Szlávik, Miklós Szolnoky and István Vályi-Nagy

Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int Antimicrobiol Agents 2020

Open access

] 17 Lakatos B, Gopcsa L, Gondos E, et al. Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology

Restricted access
Orvosi Hetilap
Authors: Zoltán Hella, László Hodinka, Piroska Turbucz and Gábor László Kovács

, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional

Restricted access
Orvosi Hetilap
Authors: Fruzsina Benyó, Alexandra Farkas, Hajnalka Horváth, Zoltán Zsolt Nagy and Zsuzsanna Szepessy

: sirolimus as a therapeutic approach for uveitis. Transl Vis Sci Technol. 2015; 4: 4. 14 Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non

Open access
Orvosi Hetilap
Authors: Zoltán Sámson, Beáta Gábor, Petra Görög, Csaba Tóth, Ákos Rőthy and Zoltán Lőcsei

–1597. 13 Evans, J., Steel, L., Borg, F., et al.: Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. RMD Open, 2016, 2 (1), e000137

Restricted access

Kawashiri, S. Y., Kawakami, A., Yamasaki, S., et al.: Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol. Int., 2010, 31 , 451

Restricted access
Orvosi Hetilap
Authors: Ádám Remport, Zsuzsanna Gerlei, Orsolya Cseprekál, László Wagner, Katalin Földes, Adrienn Marton, Attila Patonai, Szilárd Török, Anita Haboub-Sandil, Marina Varga, Attila Doros, Anikó Smudla, János Fazakas and László Kóbori

Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117: 10970–10975. 49

Open access